RT Journal Article
T1 Beyond visual acuity: Patient-relevant assessment measures of visual function in retinal diseases
A1 Puell Marín, María Cinta
A1 Contreras Martín, Inés
A1 Pinilla Lozano, Isabel
A1 Escobar Barranco, José Juan
A1 Soler García, Antonio Manuel
A1 Blasco, Antonio Javier
A1 Lázaro, Pablo
AB Purpose: To identify patient-reported outcomes (PROs) and other clinical outcome measures (contrast sensitivity (CS), low-luminance visual acuity (LLVA) and reading acuity or reading speed (RA-RS)), relevant to patients with age-related macular degeneration (AMD) or diabetic retinopathy (DR), which would be recommended for use in clinical practice.Methods: The RAND/UCLA Appropriateness Method, based on the synthesis of the scientific evidence and the collective judgment of an expert panel using the two-round Delphi method, was applied. The evidence synthesis was performed by searching for articles on outcome measures for AMD and/or DR published between 2005 and 2018 in English or Spanish. The expert panel consisted of 14 Spanish ophthalmologists, who rated the recommendation degree for each outcome measure on a scale of 1 (extremely irrelevant) to 9 (maximum relevance). The recommended outcome measures were established according to the panel median score and the level of the panelists’ agreement.Results: Through the evidence search, 33 PRO-specific questionnaires (21 for visual function, six for AMD, three for DR, one for AMD and DR) and two treatment satisfaction questionnaires (one on AMD and one on DR) were identified. In addition, 21 methods were found for measuring CS, five for LLVA, and nine for RA-RS. According to the panel ratings, 11 of the 64 outcome measures evaluated for AMD, and seven of the 61 evaluated for DR were recommended.Conclusion: The AMD and DR outcome measures recommended will help ophthalmologists choose the outcome measure most appropriate for their patients. Furthermore, the use of PROs will contribute to shifting clinical practice towards patient-centered medicine.
PB SAGE Publications
SN 1120-6721, ESSN: 1724-6016
YR 2021
FD 2021-01-22
LK https://hdl.handle.net/20.500.14352/7757
UL https://hdl.handle.net/20.500.14352/7757
LA eng
DS Docta Complutense
RD 13 oct 2025